PRME

Several events have impacted Prime Medicine's stock price in the past six months. The company reported its full-year 2025 financial results and flagged a "going concern" risk, indicating a need for additional funding. The company reported a quarterly loss of $0.28 per share, missing estimates. Analysts have issued price targets for PRME, with a median target of $7.50 to $8.50. Svetlana Makhni was appointed as Chief Financial Officer. Prime Medicine's stock has traded between $1.11 and $6.94 over the past 52 weeks, gaining 143.2% over the past 12 months but declining in shorter recent periods. There have been reports of insider purchases.